Quarterly Report Card: Comprehensive Research on Remy International, RF Industries, Roka Bioscience, Schmitt Industries and Sequenom

NEW YORK, December 22, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Remy International (NASDAQ: REMY), RF Industries (NASDAQ: RFIL), Roka Bioscience (NASDAQ: ROKA), Schmitt Industries (NASDAQ: SMIT), and Sequenom (NASDAQ: SQNM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

REMY Research Report: ( http://get.analystsreview.com/pdf/?c=Remy%20International&d=22-Dec-2014&s=REMY ),

RFIL Research Report: ( http://get.analystsreview.com/pdf/?c=RF%20Industries&d=22-Dec-2014&s=RFIL ),

ROKA Research Report: ( http://get.analystsreview.com/pdf/?c=Roka%20Bioscience&d=22-Dec-2014&s=ROKA ),

SMIT Research Report: ( http://get.analystsreview.com/pdf/?c=Schmitt%20Industries&d=22-Dec-2014&s=SMIT ),

SQNM Research Report: ( http://get.analystsreview.com/pdf/?c=Sequenom&d=22-Dec-2014&s=SQNM ).

============

--

Analyst Update: Merger Updates, Dividends, Quarterly Results, and Settlements

Reviewed by: Rohit Tuli, CFA®  

The U.S. markets extended their gains for a third session on Friday with the S&P 500 adding up its second best week in almost two years. The Dow Jones Industrial Average finished at 17,804.80, up 0.15%, the NASDAQ Composite edged 0.36% higher at 4,765.38, and the S&P 500 advanced 0.46% to close the session at 2,070.65. The rally in the U.S. stocks was fueled by the Federal Reserve's assurance on Wednesday to take a patient approach towards raising interest rates, which calmed the investors over the policy outlook. On the other hand, the European markets ended Friday's session on a mixed note as Italian banking and healthcare stocks weighed down the wider benchmarks. The Asian markets extended the previous day's gain on Friday and ended on a positive note boosted by the momentum on Wall Street following the reassurance from Federal Reserve that interest rates would be hiked no sooner than mid-2015.

Remy International, Inc. (Remy) will hold a special meeting of its shareholders on December 31, 2014, to seek approval of the previously announced merger agreement among Remy International, Inc., (old Remy), Fidelity National Financial, Inc. (FNF), New Remy Holdco Corp. and several wholly owned subsidiaries of FNF (the transaction).

RF Industries, Ltd.'s (RF Industries) board has declared a quarterly cash dividend of $0.07 per common share, payable on January 15, 2015 to shareholders of record on December 31, 2014. Earlier, the Company has also signed a non-binding term sheet to acquire Comnet Telecom Supply, Inc. (Comnet) for cash and stock.

Roka Bioscience, Inc.  (Roka Bioscience) reported solid 166.7% YoY increase in its revenue for third quarter 2014. The said improvements were attributed to increase in the number of Atlas instruments placed with commercial customers and increased commercial utilization of the instruments.

Schmitt Industries, Inc. (Schmitt Industries) is on road to recovery as it reported net income of $51,783 or $0.02 per diluted share during fiscal first quarter 2015 compared with net loss of $146,559 or $0.05 per diluted share in corresponding period of prior year.

Sequenom, Inc. (Sequenom), along with Illumina, Inc. (Illumina), has decided to settle all its pending violation claims and other disputes between Sequenom and Verinata Health, Inc. The Companies will combine their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference proceedings.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED